Kite, a Gilead Sciences company based in Santa Monica, CA, specializes in extensive cell therapy development and commercialization and manufacturing. Shoreline is developing a pipeline of natural killer cell and macrophage cell therapy candidates based on induced pluripotent stem cell (iPSC) differentiation methods and genetic reprogramming of pathways relevant to diseases.

Shoreline will receive an undisclosed upfront payment and will be eligible to receive additional payments totaling over $2.3 billion, as well as royalties based on achievement of certain development and commercial milestones, the companies said.

Shoreline secures $43M to advance cell therapy products
Shoreline Biosciences has raised $43 million in capital to accelerate the advancement of its induced pluripotent stem cell platform, focused on the...

Gilead partners with Gritstone for HIV vaccine, increases investment in Arcus
Gilead Sciences said it's collaborating with Gritstone Oncology to develop a vaccine-based immunotherapy aimed at providing a curative treatment for HIV....

Kite, Oxford BioTherapeutics partner on novel oncology targets
Kite, a Gilead company, and Oxford BioTherapeutics have entered into a research collaboration to evaluate five novel cell therapy targets for hematologic...

Kite submits BLA for CAR T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel...